Trevi Therapeutics (TRVI) Cash from Operations (2018 - 2026)

Trevi Therapeutics has reported Cash from Operations for 9 years, with the latest figure at 16689000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 23.83% year-over-year to 16689000.0; the trailing twelve-month figure through Mar 2026 stood at 45301000.0 (down 9.78% YoY), and the FY2025 full-year result was 42089000.0, down 10.02% from the prior year.
• Cash from Operations for Q1 2026 stood at 16689000.0, down from 7631000.0 in the prior quarter.
• The five-year high for Cash from Operations was 6176000.0 in Q2 2022, with the low at 16689000.0 in Q1 2026.
• Average Cash from Operations over 5 years is 9230529.41, with a median of 8683000.0 recorded in 2024.
• Year-over-year, Cash from Operations climbed 21.8% in 2022 and tumbled 59.89% in 2023.
• Tracing TRVI's Cash from Operations over 5 years: stood at 6331000.0 in 2022, then declined by 0.44% to 6359000.0 in 2023, then tumbled by 50.18% to 9550000.0 in 2024, then gained by 20.09% to 7631000.0 in 2025, then slumped by 118.7% to 16689000.0 in 2026.
• The last three Cash from Operations figures came in at 16689000.0 (Q1 2026), 7631000.0 (Q4 2025), and 10880000.0 (Q3 2025), per Business Quant data.

Peer Comparison